Price
No data yet.
Social Signal Score
Revenue
$15.8K-94.07%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andre Larente
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 22
- Beta
- -0.15
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -19.80
Financials
Revenue
$15.8K-94.1%Net Income
$-1.19MEBITDA
$-1.12MFree Cash Flow
$-1.32MEPS (diluted)
$-0.01Shares Outstanding (diluted)
120.41M+1034.2%Operating Expenses
$791.6KCash & Debt
$1.93MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $65.6K | $-4.57M | $-0.04 |
| 2025 | $103.8K | $-4.29M | $-0.05 |
| 2024 | $170.2K | $-3.12M | $-0.04 |
| 2023 | $438.8K | $-2.61M | $-0.04 |
| 2022 | $267.1K | $-2.05M | $-0.03 |
| 2021 | $331.5K | $-3.38M | $-0.05 |
| 2020 | $326.5K | $-3.84M | $-0.09 |
| 2019 | $326.5K | $-3.84M | $-0.20 |
| 2018 | $1.61M | $-2.90M | $-0.17 |
| 2017 | $2.39M | $-2.93M | $-0.24 |
| 2016 | $981.5K | $-3.19M | $-0.30 |
| 2015 | $564.2K | $-2.83M | $-0.29 |
| 2014 | $2.70M | $-1.64M | $-0.21 |
| 2013 | $1.51M | $-2.04M | $-0.31 |
Valuation
DGNOFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-11.11%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·6h ago·Negative
DIAGNOS Provides an Update on Stock Warrants BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.
View source ↗ - Newsglobenewswire.com·22d ago·Positive
…ng of Shareholders on September 30, 2026 BROSSARD, Quebec, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health pathologies using Artificial Intelligence (AI) techniques, announces that the 2026 annual general meeting of shareholders (the “Meeting”) will be held on September 30, 2026, at 10:00 a.m., in person, at Alt Quartier DIX30 Hotel, 6500 de Rome Blvd, 2n…
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…ed Retinal Image Analysis to Saudi Arabia BROSSARD, Quebec, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that today, August 13, 2026, it has received Medical Device Marketing Authorization for the CARA System (CARA) from the Saudi Food and Drug Authority (SFDA). The version of CAR…
View source ↗
Earnings
Tue, Dec 1(in 8 weeks)
Consensus estimate $-0.01 per share
- Thu, Jun 11$-0.01 vs $-0.01miss
- Thu, Nov 20$-0.01 vs $-0.01miss
- Wed, Aug 20$-0.01 vs $-0.01miss
- Wed, May 28$-0.01 vs $-0.01miss
- Wed, Feb 12$-0.01 vs $-0.01miss
Estimates and results for DGNOF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in DGNOF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.